Radiotherapy News and Research

RSS

Radiation therapy (in North America), or radiotherapy (in the UK and Australia) also called radiation oncology, and sometimes abbreviated to XRT, is the medical use of ionizing radiation as part of cancer treatment to control malignant cells (not to be confused with radiology, the use of radiation in medical imaging and diagnosis).

Skin patch treatment kills common skin cancer

A skin patch treatment for basal cell carcinoma effectively destroys facial tumors in most patients without the need for surgery or major radiation, researchers report.

25 Jun 2012

International conference showcases breadth of research possible with zebrafish

It's clear where the black-and-white striped zebrafish got its name, but less obvious at first glance is what zebrafish has to do with biomedical research. Amazingly, it has biological similarities to humans, which are making this small freshwater fish an increasingly popular model organism for studying vertebrate development, genetics, physiology, and mechanisms of disease.

23 Jun 2012

Skin patch treatment kills common skin cancer

A skin patch treatment for a common type of skin cancer called basal cell carcinoma effectively destroys facial tumors in most patients without the need for surgery or major radiation, researchers report.

22 Jun 2012

Aeterna Zentaris announces perifosine Phase 1 trial on neuroblastoma

Aeterna Zentaris Inc. today announced that Phase 1 trial results for its oral PI3K/Akt inhibitor, perifosine, showed the drug's activity against chemo-resistant and radio-resistant neuroblastoma, while allowing good quality of life and sparing vital organs. Neuroblastoma is a type of childhood cancer which usually begins in nerve tissues.

22 Jun 2012

Concord Medical acquires 52% equity ownership in Chang'an Hospital

Concord Medical Services Holdings Limited, a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China, announced today that it has closed the acquisition of 52% equity ownership in Chang'an Hospital, a leading non-public general hospital located in Xi'an, Shaanxi Province.

18 Jun 2012

Agility MLC's new design provides better dose sculpting capabilities

Requiring only a quick upgrade to their existing Elekta Synergy linear accelerator, physicians at SALK and Paracelsus Medical University began using the new Agility 160-leaf multileaf collimator (MLC), treating 33 patients on its first day. In its first month of Agility use, the center now treats 50 patients per day, comprising about 700 individual treatment sessions that have benefited from this breakthrough in cancer care.

From Elekta 18 Jun 2012

NHS Supply Chain signs deal to purchase 10 Elekta Synergy radiation therapy treatment systems

NHS Supply Chain will bring state-of-the-art cancer treatment to the United Kingdom by signing a deal to purchase ten Elekta Synergy radiation therapy treatment systems.

From Elekta 18 Jun 2012

Stereotactic ablative radiotherapy benefits stage I non-small cell lung cancer patients

Until recently, many elderly patients with stage I non-small cell lung cancer were left untreated because treatment may not improve their quality of life. However, stereotactic ablative radiotherapy (SABR) has become one of the standards of treatment for these patients. The outpatient treatment given over a two-week period allows frail patients to undergo the treatment.

16 Jun 2012

Researchers identify three sets of genetic markers linked with CNS PNET

Researchers at The University of Nottingham have identified three sets of genetic markers that could potentially pave the way for new diagnostic tools for a deadly type of brain tumour that mainly targets children.

16 Jun 2012

DFINE completes initial phase of STAR Tumor Ablation System trial

DFINE, Inc., the developer of minimally invasive radiofrequency (RF) targeted therapies for the treatment of vertebral pathologies, today announced an upcoming poster presentation at the World Congress of Interventional Oncology (WCIO), June 14-18 in Chicago.

15 Jun 2012

Advaxis announces publication of preclinical research with ADXS-PSA

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced the publication of preclinical research with ADXS-PSA (ADXS31-142), Advaxis' Lm-LLO immunotherapy targeting the PSA antigen associated with prostate cancer.

14 Jun 2012

AMS announces FDA clearance of MEVION S250 Proton Therapy System

AMERICAN SHARED HOSPITAL SERVICES, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today shared a recent announcement from Mevion Medical Systems, Inc. regarding Mevion Medical Systems' receipt of FDA 510(k) clearance for its MEVION S250 Proton Therapy System.

12 Jun 2012

ColoPrint aids prediction of colorectal cancer relapse

A novel microarray-based 18-gene expression tool known as ColoPrint significantly improves prognostic accuracy in stage II colon cancer patients who have undergone surgery, suggest study findings.

11 Jun 2012

FDA clears MEVION S250 Proton Therapy System

Mevion Medical Systems, Inc., a radiation therapy company dedicated to advancing the treatment of cancer, announced today that it has received FDA 510(k) clearance for its MEVION S250 Proton Therapy System.

11 Jun 2012

NKI-AVL, Elekta partner to advance cancer research

Elekta and The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital have signed a strategic alliance to advance cancer research.

From Elekta 8 Jun 2012

Split-course RT valuable after hormone-resistant prostate cancer relapse

A split course of high-dose radiotherapy in men with progressive, hormone-refractory prostate cancer is effective and has an acceptable toxicity profile, report Australian researchers.

6 Jun 2012

New data from OncoMed’s OMP-59R5 Phase I study on advanced solid tumors

OncoMed Pharmaceuticals, Inc., a privately held, clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor initiating cells, today highlighted new data presented this afternoon in a poster discussion session at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL.

4 Jun 2012

'Atzelberg Circle' researchers meet to advance hyperthermia as standard combination cancer therapy

BSD Medical Corporation, a developer and manufacturer of advanced medical systems that utilize heat therapy to treat cancer, announced today that a distinguished, international team of leading oncologists met in council while attending the May 2012 conference of the European Society for Radiotherapy and Oncology (ESTRO) in Barcelona, Spain.

2 Jun 2012

Agendia launches ColoPrint microarray-based 18-gene expression signature for colon cancer

Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced the launch of its ColoPrint microarray-based 18-gene expression signature for predicting the risk of distant recurrence for stage II colon cancer patients who have undergone surgery.

2 Jun 2012

Inhibiting IRE1α-XBP1 pathway impacts survival of myeloma cells

Results published in Blood, the official journal of the American Society of Hematology, confirm that inhibition of the IRE1α-XBP1 pathway impacts the survival of myeloma cells, suggesting a promising therapeutic option in multiple myeloma.

2 Jun 2012